PGP and amyotrophic lateral sclerosis: This study showed that EV-delivered CRISPR/Cas9 was effective in inhibiting P-gp, making it easier for medications that treat diseases of the brain like Alzheimer’s, amyotrophic lateral sclerosis (ALS), epilepsy, among others, to cross the BBB with improved efficiency [26].